Rapid angiogenesis occurs as the ovulatory follicle is transformed into the corpus luteum. To determine if luteinizing hormone (LH)-stimulated prostaglandin E2 (PGE2) regulates angiogenesis in the ovulatory follicle, cynomolgus macaques received gonadotropins to stimulate multiple follicular development and chorionic gonadotropin (hCG) substituted for the LH surge to initiate ovulatory events. Before hCG, vascular endothelial cells were present in the perifollicular stroma but not amongst granulosa cells. Endothelial cells entered the granulosa cell layer 24-36 h after hCG, concomitant with the rise in follicular PGE2 and prior to ovulation, which occurs about 40 h after hCG. Intrafollicular administration of the PG synthesis inhibitor indomethacin was coupled with PGE2 replacement to demonstrate that indomethacin blocked and PGE2 restored follicular angiogenesis in a single, naturally developed monkey follicle in vivo. Intrafollicular administration of indomethacin plus an agonist selective for a single PGE2 receptor showed that PTGER1 and PTGER2 agonists most effectively stimulated angiogenesis within the granulosa cell layer. Endothelial cell tracing and three-dimensional reconstruction indicated that these capillary networks form via branching angiogenesis. To further explore how PGE2 mediates follicular angiogenesis, monkey ovarian microvascular endothelial cells (mOMECs) were isolated from ovulatory follicles. The mOMECs expressed all four PGE2 receptors in vitro. PGE2 and all PTGER agonists increased mOMEC migration. PTGER1 and PTGER2 agonists promoted sprout formation while the PTGER3 agonist inhibited sprouting in vitro. While PTGER1 and PTGER2 likely promote the formation of new capillaries, each PGE2 receptor may mediate aspects of PGE2's actions and, therefore, LH's ability to regulate angiogenesis in the primate ovulatory follicle.
INTRODUCTION
Angiogenesis within the primate ovarian follicle is essential for ovulation and formation of the corpus luteum. Vascular endothelial growth factor (VEGF) is well established as a major regulator of follicular angiogenesis. Studies utilizing VEGF Trap R1R2 and VEGF antagonists such as soluble VEGF receptor 1 have demonstrated that blocking VEGF action within the follicle disrupts follicle rupture, oocyte release, and subsequent luteal function [1, 2] . Administration of antiangiogenic agents such as TNP-470, Ang-2, and the thrombospondin-mimetic peptide ABT-898 or neutralization of delta-like ligand 4 (Dll4) also prevent normal ovulation and luteinization [3] [4] [5] [6] . Taken together, these studies demonstrate that disruption of angiogenesis during the ovulatory interval prevents normal ovulatory events. To date, studies of ovarian angiogenesis have focused on either preovulatory follicles or the development and maintenance of the corpus luteum. Few studies have addressed the initiation of vessel formation within the granulosa cell layer either in response to a natural surge of luteinizing hormone (LH) or from experimental cycles employing human chorionic gonadotropin (hCG) as an ovulatory stimulus.
Prostaglandin production by the primate ovarian follicle is required for ovulation. Granulosa cell synthesis of prostaglandins is triggered by the ovulatory LH surge, and prostaglandins reach peak levels within the follicle just prior to ovulation [7, 8] . Prostaglandin E2 (PGE2) has been identified as the key ovulatory prostaglandin in primates [9] . PGE2 acts via four distinct receptors, referred to as PTGER1, PTGER2, PTGER3, and PTGER4. These receptors couple to different G proteins and regulate distinct signal transduction pathways [10] . Therefore, cellular responses to PGE2 depend, at least in part, on the PTGER(s) expressed.
PGE2 and PTGER signaling modulate angiogenesis in pathological circumstances, such as tumor growth [11] . Comparatively little is known about how PGE2 directs angiogenesis in healthy tissues such as the ovulatory follicle. To determine if PGE2 mediates the ability of the ovulatory LH surge to direct angiogenesis in the primate ovulatory follicle, we examined PTGER expression and PTGER responses in endothelial cells of primate ovulatory follicles. Our results show that the ability of the ovulatory gonadotropin surge to stimulate angiogenesis is mediated by PGE2, which contributes to the formation of new, capillary-like structures among the granulosa cells. We further demonstrate that all four PTGERs are expressed by follicular endothelial cells and that endothelial cells respond to PTGER-selective agonists in a manner consistent with a role for each PGE2 receptor in follicular angiogenesis.
MATERIALS AND METHODS

Animals
Ovaries were obtained from adult female cynomolgus macaques (Macaca fascicularis) at Eastern Virginia Medical School (Norfolk, VA). All the animal protocols were approved by the Eastern Virginia Medical School Animal Care and Use Committee and were conducted in accordance with the National Institutes of Health's Guide for the Care and Use of Laboratory Animals.
Briefly, adult females with normal menstrual cycles were maintained as previously described [12] . Blood samples were obtained under ketamine chemical restraint (5-10 mg/kg body weight). Serum steroids were determined using the Immulite 1000 immunoassay system (Siemens Medical Diagnostics Solutions). Aseptic surgeries were performed by laparotomy or laparoscopy in a dedicated surgical suite with appropriate anesthesia (1%-2% isofluorane gas vaporized in 100% oxygen) and comprehensive monitoring.
Ovarian Stimulation
An ovarian stimulation model was used to obtain ovaries with multiple ovulatory follicles [13, 14] . Briefly, monkeys received 90 international units (IU) of recombinant human FSH (Merck) for 6-8 days, followed by 90 IU of FSH plus 60 IU of recombinant human LH (Serono) for 2-3 days to stimulate the growth of multiple follicles. Animals also received a GnRH antagonist (0.5 mg/kg Antide [Serono] or 0.03 mg/kg Ganirelix [Merck]) daily to prevent an endogenous LH surge. Follicular development was monitored by ultrasonography and rising serum estradiol. Ovaries were removed either before (0 h) or 12, 24, or 36 h after administration of 1000 IU of recombinant hCG (Serono). Ovarian pieces were either fixed in 10% formalin and embedded in paraffin or covered with optimal cutting temperature (OCT) compound (Sakura) and frozen in liquid propane. Additional ovaries obtained 36 h after hCG were used to isolate endothelial cells.
Controlled Ovulation
A model of controlled ovulation and follicle injection was used to administer compounds directly into the follicular fluid of a naturally selected ovulatory follicle [15] . Briefly, serum estradiol and progesterone levels were assessed daily. When estradiol levels surpassed 150 pg/ml, FSH (60 IU, Merck) and LH (60 IU, Serono) were administered once each day for 2 days to maintain the ovulatory follicle. The GnRH antagonist Acyline (60 lg/kg per day; Eunice Kennedy Shriver National Institute of Child Health and Human Development) was administered daily to prevent an ovulatory LH surge. The following day, a surgical procedure was performed to inject the preovulatory follicle [15] ; the animal then received 1000 IU hCG to initiate ovulatory events. Injected ovaries were removed 48 h after the hCG. Final concentrations of test compounds in follicles were estimated as vehicle (0.1% dimethyl sulfoxide [DMSO] in PBS), indomethacin (10 lM; Sigma), PGE2 (1 lM; Cayman), 17-phenyl-trinor-PGE2 (10 lM 17-PTP, a PTGER1 agonist; Cayman), butaprost (10 lM, a PTGER2 agonist; Cayman), sulprostone (10 lM, a PTGER3 agonist; Cayman), or PGE1 alcohol (10 lM PGE1-OH, a PTGER4 agonist; Cayman). Ovaries were fixed in 10% formalin and embedded in paraffin. Each ovary was sectioned in its entirety at 5 lm.
Monkey Ovarian Microvascular Endothelial Cells Isolation and Culture
Follicles of stimulated ovaries (n ¼ 4) were bisected, and the interior of each follicle was scraped into F-10 media (Sigma) with 1% bovine serum albumin (Sigma). Collagenase dispersal proceeded as previously described [16] . Endothelial cells were enriched using CD31 Dynabeads (Invitrogen) following the manufacturer's protocol. The resulting monkey ovarian microvascular endothelial cells (mOMECs) were plated on fibronectin-coated tissue cultureware and maintained in EGM-2MV (EGM2) media (Lonza). This media is optimized for culture of microvascular endothelial cells and contains serum as well as growth factors, including VEGFA, hydrocortisone, fibroblast growth factor 2 (FGF2), insulinlike growth factor 1 (IGF1), and epidermal growth factor (EGF). A second Dynabead isolation was performed at the second passage, resulting in a proliferating primary cell population of greater than 95% endothelial cells as described below. Additional bead isolations were performed every fifth passage. The mOMECs maintained their endothelial cell phenotype for at least 16 passages. However, the rate of cell proliferation declined rapidly after about 14 passages. A conservative choice was made to perform these experiments on mOMECs from passages four to nine. Subtle differences were observed between mOMEC lines in terms of sprouting and migration. Overall, consistent direction and magnitude of changes are reflected in the data.
Isolated mOMECs possessed characteristics of endothelial cells. Confluent cells were cobblestone in appearance (Fig. 1A) . Cells were also shown to take up acetylated low density lipoprotein (dil-Ac-LDL; Invitrogen), characteristic of endothelial cells. Briefly, cells were incubated with dil-Ac-LDL following the manufacturer's instructions and counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI, Invitrogen); at least 95% of cells were positive for dil-Ac-LDL (Fig. 1B) . At least 95% of cells were immunopositive for von Willebrand Factor (vWF) as described below (Fig. 1C) ; cells were negative for smooth muscle actin (SMA) and 3b-hydroxysteroid dehydrogenase (HSD3B), markers for smooth muscle and steroidogenic cells, respectively (data not shown). Flow cytometry for Ulex europaeus agglutinin-1 (UEA-1) was performed as primate endothelial cells bind UEA-1 [17] . Briefly, 1 3 10 6 cells were resuspended in Hank buffer plus 1% bovine serum albumin and mixed with fluorescein isothiocyanate (FITC)-conjugated UEA-1 (Vector Laboratories) or no lectin for 30 min on ice, fixed in 1% formalin, and characterized using a Becton Dickinson FACSCalibur flow cytometer and FlowJo analysis software. At least 95% of cells were UEA-1 þ (Fig. 1D ).
Immunohistochemistry
Paraffin-embedded ovaries were sectioned at 5 lm and immunostained essentially as previously described [12] . Tissue sections were blocked with 5% nonimmune serum in PBS plus 0.1% Triton X-100, incubated overnight with antibody against vWF (7.75 lg/ml; Dako), color developed using a rabbit ABC kit (Vector), and counterstained in hematoxylin. The mOMECs were grown to confluence on chamber slides for characterization. Confluent cells were fixed in 10% formalin for 20 min and then blocked as described above. Staining proceeded as described for paraffin sections using antibodies against either vWF (7.75 lg/ml; Dako), HSD3B (1:2000; Dr. Ian Mason, University of Edinburgh, MRC Center for Reproductive Health), or SMA (0.067 lg/ml; Thermo Fisher).
For Ki67 immunodetection, mOMECs were grown to 60% confluence, switched to basal medium (EBM-2; Lonza) overnight, then to basal media with the addition of 1 lM PGE2 or an individual PTGER agonist (10 lM 17-PTP, 10 lM butaprost, 1 lM sulprostone, or 1 lM PGE1-OH). Addition of basal medium or EGM2 served as negative or positive controls, respectively. After 24 h, cells were fixed and stained as described above using an antibody directed against Ki67 (0.35 lg/ml; Dako). For each mOMEC line, four images were obtained for each treatment. Positive and negative nuclei were counted; the percentage of Ki67-positive nuclei was determined for each treatment.
All the images were obtained using an Olympus BX41 microscope fitted with a DP70 digital camera and associated software. Omission of the primary antibody served as a negative control. TRAU ET AL.
Immunofluorescence
The mOMECs were grown to confluence, fixed, and blocked as described above. Slides were incubated with an antibody directed against a single PGE2 receptor (PTGER1 (2 lg/ml), PTGER2 (10 lg/ml), PTGER3 (4 lg/ml), or PTGER4 (6 lg/ml); Cayman), followed by Alexa Fluor 488-conjugated antirabbit secondary antibody (1:200; Molecular Probes). Slides were incubated in 1% Sudan Black in 70% methanol and counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI). Preabsorption of each primary antibody with the peptide used to generate the antibody (Cayman) and omission of primary antibody served as negative controls. Images were obtained as described above.
For dual staining of frozen ovary sections for vWF and an individual PTGER, the vWF antibody was direct labeled with Alexa-555 following the manufacturer's instructions (Molecular Probes). Slides were fixed in acetone for 10 min, blocked in 5% nonimmune serum, and incubated with an individual PTGER antibody overnight, followed by Alexa Fluor 488-conjugated antirabbit secondary antibody as described above. Slides were then incubated with the Alexa-555 direct-labeled vWF primary antibody for 2 h before exposure to 1% Sudan Black and counterstained with To-Pro-3 (Invitrogen). Slides were imaged using a Zeiss LSM 510 confocal microscope and associated software.
Three-Dimensional Reconstructions
Serial sections from controlled ovulation ovaries were immunostained for vWF and imaged as described above. The vWF þ cells from at least four adjacent 5 lm sections were traced into WinSurf software (SURFdriver) and aligned following the manufacturer's instructions using an approach similar to that previously described [18] .
RNA Isolation, Amplification, and Quantitative PCR
The mOMECs were grown as described above and treated as described for immunohistochemistry. Total RNA was harvested using Trizol (Invitrogen), treated with DNase, and reverse transcribed as previously described [19] . Quantitative PCR was performed using a Roche LightCycler and FastStart DNA Master SYBR Green I kit (Roche Diagnostics). Primers and reaction conditions for quantitative detection of cynomolgus macaque PTGERs and bactin (ACTB) mRNAs were previously described [20] . All the data are expressed as the ratio of PTGER to ACTB.
Western Blot Detection of PTGERs
Western blot analysis was performed as previously described [21] . Briefly, cell lysates were separated on a 10% polyacrylamide Tris-HCl gel (Bio-Rad), transferred to a polyvinylidene fluoride membrane (Immobilon; Millipore), and probed using antibodies against PTGERs (PTGER1 [2.5 lg/ml], PTGER2 [2.5 lg/ml], PTGER3 [2.5 lg/ml], or PTGER4 [5 lg/ml;]) or pan-actin (1:1000; Millipore). Membranes were incubated with anti-rabbit or anti-mouse alkaline phosphatase-conjugated antibody (1:5000; Applied Biosystems), and the protein bands were visualized with Tropix CDP-Star (Applied Biosystems).
Intracellular Signaling
Intracellular calcium was assessed using the Fluo-4 NW Calcium Assay Kit (Molecular Probes) as previously described [22] . Briefly, cells were grown to confluence in a 96-well plate. Media was replaced with Fluo-4 NW dye in assay buffer, and the plate was incubated in the dark at 378C for 30 min, then at room temperature for 30 min. PTGER agonists (final concentrations listed above for immunohistochemistry) and thrombin (16.2 lg/ml; Cayman) were prepared in assay buffer. Basal fluorescence was measured before treatment (0 sec) using an excitation at 494 nm and emission at 516 nm, then again following addition of agonist every 20 sec for 2 min in a SpectraMax microplate reader (Molecular Devices). Exposure to the calcium ionophore calcimycin (CalBiochem) served as a positive control.
To assess cAMP levels, cells were grown to 80% confluence, then switched to basal media with 1% fetal bovine serum overnight before treatment with PGE2 or PTGER agonists (at concentrations listed above for immunohistochemistry) or isoproterenol (2 lM; Sigma) in basal media for 8 h. Media were harvested and stored at À208C until assay for cAMP by enzyme immunoassay (EIA; Cayman) as previously described [22] .
Proliferation Assay
Proliferation was measured using the MTT Cell Proliferation Assay (ATCC). For each treatment condition, cells (5000 per well) were plated in triplicate, along with blank wells, and allowed to settle overnight. The next morning, basal media with vehicle, PGE2, or a PTGER agonist (at concentrations listed above for immunohistochemistry) was added to the wells; additional wells treated with EGM2 media served as a positive control. Plates were incubated 24 h before the addition of MTT reagent. Preliminary experiments were conducted using 2500-20 000 cells per well and incubation times of 4-72 h identified optimal conditions (data not shown).
Migration Assay
Six-well plate inserts with 8 lm pores (BD) were prepared with 150 000 cells in basal media inside the insert. Media in the well consisted of basal media with or without the addition of PGE2, a PTGER agonist (at concentrations listed above for immunohistochemistry), or PTGER antagonist (PTGER1: GW848687x, 2.5 lM [Cayman]; PTGER2: PF-04418948, 18 lM [Cayman]; PTGER3: L-798106, 0.03 lM [Sigma]; or PTGER4: GW627368x, 10 lM [Cayman]); EGM2 in the well served as a positive control. For each PTGER antagonist, several log dilutions were tested in two mOMEC lines to determine the lowest dose of each antagonist that inhibited PTGER selective agonistinduced migration (data not shown). Cells were incubated for 24 h, then cells on the inside of the insert were removed with a cotton swab. The inserts were fixed in 70% ethanol and stained with hematoxylin and eosin. Four areas of each insert were photographed as described above, and the number of migrated cells was counted for each image.
Sprouting Assay
Cells were added to Cytodex microcarrier beads (500-1000 cells per bead; GE Healthcare) and embedded in a fibrin matrix as previously described [23] . Fibrin matrixes were prepared containing approximately 100 cell-coated microcarrier beads in 0.5 ml matrix material. Basal media plus 0.05 U/ml aprotinin with or without the addition of PGE2 or a PTGER agonist (at concentrations listed above for immunohistochemistry) was added on top of matrixes; EGM2 media was used as a positive control. For each well, five areas were photographed 24 h after initiation of cultures using an Olympus CK40 microscope, Infinity Lite camera, and associated software (Lumenera). Each image was printed at the same scale, and beads with sprouts that were entirely within the frame were used to generate sprout counts and measurements. For sprout counts, the number of sprouts per bead was determined, and an average number of sprouts/bead was determined for each treatment group. Sprouts were measured from the edge of the bead to the tip of the longest branch; lengths were averaged for each treatment group.
Data Analysis
Data were assessed for heterogeneity of variance by Bartlett tests. Data were log transformed when the Bartlett test yielded P , 0.05; log-transformed data were subjected to the Bartlett test to confirm that P . 0.05. All the data sets were assessed by paired t-test or ANOVA (without or with repeated measures) as indicated in the text or figure legends followed by Duncan multiple range test (StatPak version 4.12 software; Northwest Analytical). Significance was assumed at P , 0.05. Data are expressed as mean 6 SEM.
RESULTS
The Midcycle Gonadotropin Surge Stimulates Angiogenesis in the Ovulatory Follicle
Vascular endothelial cells are restricted to the stroma of the follicle prior to the ovulatory gonadotropin surge [24] . To determine when after the ovulatory gonadotropin surge endothelial cells are present in the granulosa cell layer, ovaries from monkeys experiencing ovarian stimulation were obtained before and after administration of an ovulatory dose of hCG at time points spanning the ovulatory interval, and immunohistochemical detection of vWF was used to identify endothelial cells. Prior to hCG (0 h) and 12 h after hCG, vWF þ cells were restricted to the stroma surrounding the ovulatory follicle (Fig.  2, upper panels) . However, vWF þ cells were observed in both the stroma and extending into the granulosa cell layer 24 and 36 h following hCG (Fig. 2, upper panels) .
PGE2 PROMOTES ANGIOGENESIS IN OVULATORY FOLLICLES
Each PGE2 Receptor Regulates Follicular Angiogenesis In Vivo
The appearance of vWF þ cells in the granulosa cell layer correlates with the LH-stimulated elevation of PGE2 levels within the ovulatory follicle [8] , suggesting that PGE2 may regulate these events. In order to respond directly to PGE2, endothelial cells must express PTGERs. To determine if endothelial cells of primate ovulatory follicles express PTGERs, ovarian tissues obtained after ovarian stimulation and 36 h of exposure to hCG were dual immunostained for vWF and a single PTGER (Fig. 2, lower panels) . Each PTGER colocalized with vWF þ cells within the granulosa cell layer. Endothelial cells in the stroma surrounding the ovulatory follicles expressed PTGER3 and PTGER4; colocalization of either PTGER1 or PTGER2 with vWF was not observed in the follicular stroma. Granulosa cells also stained positively for each PTGER, consistent with our previous reports [20, 25] , although staining conditions here were optimized for detection of PTGERs in endothelial cells.
To assess the role of PGE2 in angiogenesis of the primate ovulatory follicle in vivo, a model of controlled ovulation and intrafollicular injection was used to ablate-and-replace PGE2; ovaries were removed 48 h after follicle injection and systemic hCG administration. Follicle rupture and oocyte release occurred in all vehicle-injected follicles; histologic observations of follicle rupture and oocyte release or retention were detailed for all treatment groups in a previous report [15] . Vehicle-injected follicles contained extensive networks of vWF þ cells in the stroma surrounding the ovulatory follicle, within the granulosa cell layer, and extending toward the follicle antrum (Fig. 3A) . In contrast, follicles injected with the prostaglandin synthesis inhibitor indomethacin showed no vWF þ cells in the granulosa cell layer; instead, vWF þ cells were restricted to the stroma surrounding the injected follicle (Fig. 3B) . Injection of indomethacin plus PGE2 resulted in networks of endothelial cells similar to those observed after vehicle treatment, confirming that PGE2 replacement restored indomethacin-inhibited angiogenic events (Fig. 3C) .
Further studies utilized this ablate-and-replace approach to examine the ability of each PTGER to promote follicular angiogenesis. Injection of indomethacin plus PTGER1 agonist yielded many vWF þ cells near stromal invaginations, with some vWF þ cells among the granulosa cells and extending toward the follicle antrum (Fig. 3E) . Treatment with indomethacin plus PTGER2 agonist also resulted in vWF þ cells in both the stroma and the granulosa cell layer, some of which surrounded unusually large luminal spaces that were not seen in vehicle or indomethacin plus PGE2-treated follicles (Fig.  3F) . PTGER2 agonist treatment did not yield the long networks of vWF þ cells extending toward the follicle antrum as seen after vehicle or indomethacin plus PGE2 treatment (Fig. 3F) . Injection of indomethacin plus PTGER3 agonist yielded few vWF þ cells just across the follicle basement membrane amongst the granulosa cells; most vWF þ cells were restricted to the stroma surrounding the injected follicle (Fig. 3G) . Injection of indomethacin plus PTGER4 agonist resulted in very few vWF þ cells within the granulosa cell layer, and networks of endothelial cells were rarely observed (Fig. 3H) .
PGE2 Induces Branching Angiogenesis
New blood vessels can form in several ways, including from circulating stem cells through the process of vasculogenesis [26] and as branches from existing vessels (branching angiogenesis) [27] . The apparent networks of endothelial cells shown in Figures 2 and 3 suggest that the ovulatory gonadotropin surge and PGE2 stimulate the formation of capillary networks within the ovulatory follicle through the process of branching angiogenesis. To test this concept, adjacent ovarian sections containing follicles injected with vehicle and indomethacin plus PGE2 were immunostained for vWF and used to create three-dimensional (3D) reconstructions of endothelial cell networks (Fig. 3, I-L) . Reconstructions show that endothelial cell networks branch from larger vessels in the stroma and extend into the granulosa cell layer in both vehicle and indomethacin plus PGE2-treated follicles.
Cultured Endothelial Cells Express Functional PGE2 Receptors
Primary cultures of mOMECs were established to examine PGE2 regulation of angiogenic processes in vitro. PTGER1, PTGER2, PTGER3, and PTGER4 were detected by quantitative PCR in mOMEC cDNA (Fig. 4A) . All four PTGER proteins were detected in mOMECs by Western blot analysis [15] . I-L) Branching angiogenesis in representative follicles injected with vehicle (I, J) or indomethacin plus PGE2 (K, L). A minimum of four adjacent ovarian sections were immunostained for vWF (brown) and used to reconstruct a 3D image of vWF þ cells, which are shown as white on a black background (J, L). Each large vessel (arrows) has small branches that project into the granulosa cell layer. Representative histologic images (I, K) are shown at slightly different magnifications to include the entire area in the 3D reconstruction. (Fig. 4B) ; sizes of bands on Western blots were similar to those observed for PTGER proteins in monkey granulosa cells [20, 25] . All the PTGERs were also detected by immunofluorescence (Fig. 4, C-F) .
PGE2 PROMOTES ANGIOGENESIS IN OVULATORY FOLLICLES
PTGERs couple to G proteins, which mediate the effects of PGE2 binding. PGE2, the PTGER1 agonist, and the PTGER3 agonist each increased intracellular calcium in mOMECs; treatment with thrombin and calcimycin also increased intracellular calcium (Fig. 4G and Table 1 ). Treatment of mOMECs with PGE2, the PTGER2 agonist, and the PTGER4 agonist each increased cAMP production by mOMECs (Fig.  4H) . The PTGER3 agonist did not alter basal or isoproterenolstimulated cAMP (Fig. 4, H and I ).
Each PTGER Regulates Angiogenic Processes In Vitro
PGE2 and PTGER agonists did not alter mOMEC proliferation as assessed by the MTT assay or Ki67 expression (Fig. 5) . Proliferation as assessed by the MTT assay was increased by culture in optimal growth medium (EGM2)
FIG. 4. Each of four PTGERs is expressed and functional in mOMECs.
A) Quantitative PCR detected mRNA for PTGER1 (203 bp), PTGER2 (253 bp), PTGER3 (251 bp), and PTGER4 (228 bp) when mOMEC cDNA was included in the reaction; no amplification was seen when cDNA was omitted (water only; W). Size standards (base pairs; bp) are shown on left. Representative of n ¼ 3 mOMEC lines. B) Western blot detection of PTGER1 (75 kDa), PTGER2 (60 kDa), PTGER3 (60 and 100 kDa), PTGER4 (75 kDa), and pan-actin (actin; 45 kDa) in mOMECs; arrowheads indicate specific bands as consistent with previous reports [20, 25] . Representative of n ¼ 4 mOMEC lines. C-F) Immunodetection (green) of PTGER1 (C), PTGER2 (D), PTGER3 (E), and PTGER4 (F) in mOMECs in vitro and imaged by conventional fluorescent microscopy; nuclei are red. Inset in D shows staining when primary antibody was omitted. Bar ¼ 50 lm; images shown are at the same magnification and are representative of four mOMEC lines. G) The mOMECs responded to PGE2, the PTGER1 agonist 17-PTP, and the PTGER3 agonist sulprostone with increased intracellular calcium within 20 sec of treatment. This representative experiment shows calcium remained above basal (0 sec) levels for the 120 sec measurement period. The mOMECs also responded to thrombin with increased intracellular calcium within 20 sec of treatment; calcium dropped to intermediate levels by 60 sec but remained above basal levels throughout the 120 sec measurement period. All the cultures responded to the ionophore calcimycin with elevated calcium. For each mOMEC sample, basal level of fluorescence was set equal to 1.00; fluorescence after treatment is expressed relative to basal level for that sample, n ¼ 3-4 mOMEC lines/treatment. See Table 1 for statistical analysis. H-I) Media cAMP after treatment with media only (basal) or media with PGE2, the PTGER2 agonist butaprost, the PTGER3 agonist sulprostone, the PTGER4 agonist PGE1-OH, or the b-adrenergic agonist isoproterenol (Iso) as indicated was determined by EIA; n ¼ 4 mOMEC lines/treatment. Within H and I, groups with different superscripts are different by repeated measures ANOVA and Duncan post hoc test, P , 0.05. All the data are presented as mean 6 SEM.
TRAU ET AL. compared to basal media (0.030 6 0.008 vs. 0.021 6 0.007, P , 0.05 by paired t-test), which served as a positive control. Similarly, more nuclei contained Ki67 after culture in EGM2 media compared with basal media (84.2 6 8.8 vs. 64.1 6 3.3, P , 0.05 by paired t-test). Overall, PGE2 and PTGER agonists did not promote or inhibit mOMEC proliferation in vitro.
To determine if PGE2 induced migration of mOMECs in vitro, cells were cultured on porous membrane inserts. Treatment with PGE2 increased migration through the membrane above basal levels (Fig. 6A) . Treatment with agonists selective for each PTGER also increased mOMEC migration (Fig. 6A) . To demonstrate that each PTGER agonist was selective for a single PTGER, cells were cultured on porous membrane inserts and treated with basal media, a PTGER selective agonist, the PTGER selective antagonist for that PTGER, and the combination of agonist and antagonist (Fig. 6, B-E) . In each case, the PTGER antagonist completely blocked PTGER agonist-stimulated migration. Furthermore, each PTGER antagonist reduced or eliminated PGE2-stimulated migration (Fig. 6, F-I) .
The ability of mOMECs to form sprouts resembling capillaries was assessed by treating mOMEC-coated beads with PGE2 or an individual PTGER agonist (Fig. 7) . A few short sprouts were observed on each bead when cultured with basal media. PGE2 produced longer, more highly branched sprouts than were observed in response to basal media, but the number of sprouts was similar. The PTGER1 agonist stimulated the formation of many sprouts with few branches that were much longer than those observed in response to basal media. PTGER2 agonist treatment also produced abundant sprouts that were of similar length but more highly branched than those resulting from basal treatment. PTGER3 stimulation resulted in fewer sprouts, but the sprouts that formed were similar in length to those seen in basal cultures. Treatment with the PTGER4 agonist yielded sprouts that were similar in number and length to those seen with basal media.
DISCUSSION
The ovulatory LH surge promotes angiogenesis of the luteinizing follicle in mammals [24] . Before the LH surge, vessels and capillaries are restricted to the theca-containing stroma surrounding the granulosa cell layer. After the LH surge, stromal vessels become dilated, and blood flow to the follicle increases. In the classic reports of Corner [28] and Koering [29] , engorged vessels and networks of capillaries were observed in the stroma of the monkey follicle prior to ovulation; small vessels branching from larger stromal vessels were seen amongst luteinizing granulosa cells 2 days after ovulation. In the present study, the ability to deliver an ovulatory gonadotropin stimulus with precise timing, coupled with the ability to detect individual endothelial cells, facilitated observation of endothelial cells forming branches from stromal vessels into the granulosa cell layer in response to an ovulatory dose of hCG. Endothelial cells were present in the granulosa cell layer 36 h after hCG and prior to ovulation. Formation of endothelial cell networks in monkey luteinizing follicles was well under way 48 h after hCG, several hours after ovulation. Additional studies will be needed to quantify the extent of angiogenesis in vivo. There was no apparent decrease in the presence of endothelial cells in the follicular stroma, suggesting that stromal vessels are maintained as endothelial cells 
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proliferate and migrate to form networks in the granulosa cell layer of the luteinizing follicle. Prostaglandins mediate many of the effects of the LH surge to promote ovulation [9, 30] , and a link has been suggested between prostaglandins and ovulatory angiogenesis [24] . The timing of endothelial entry into the granulosa cell layer of the monkey follicle correlates with enhanced PGE2 levels in follicular fluid [8, 21] . Our previous studies using an ablateand-replace approach suggested that aspects of luteinization, including granulosa cell hypertrophy and reorganization of connective tissue, require PGE2 [9, 15] . In the present study, we show that capillary formation within the granulosa cell layer also requires PGE2. Follicles injected with the prostaglandin synthesis inhibitor indomethacin lacked endothelial cells within the granulosa cell layer 48 h after administration of an ovulatory dose of hCG. Injection of indomethacin plus PGE2 restored the appearance of capillaries within the granulosa cell layer similar to that seen in vehicle-treated monkeys, with endothelial cells extending from the stroma to the antral edge of the luteinizing granulosa cells. These studies demonstrate a role for PGE2 in angiogenesis of the ovulatory follicle. However, many cell types within the ovulatory follicle express receptors for PGE2, including granulosa cells, theca cells, and the oocyte [20, 25, [31] [32] [33] . For this reason, additional studies were undertaken to determine if endothelial cells respond directly to PGE2 to promote follicular angiogenesis.
Endothelial cells of the monkey ovulatory follicle expressed all four PTGERs both in vivo and in vitro. Protein of the expected sizes for each PTGER were identified by Western 
blot analysis, including multiple bands representing the isoforms of PTGER3, similar to those detected in monkey granulosa cells [20, 25] . In the monkey ovulatory follicle in vivo, each PTGER was found to be expressed by endothelial cells of the microvasculature. PTGER1 and PTGER2 were localized to endothelial cells with the appearance of capillaries within the luteinizing granulosa cells. In contrast, PTGER3 and PTGER4 were localized to both endothelial cells within the luteinizing granulosa cells and to endothelial cells of vessels in the surrounding stroma. All PTGERs were expressed by endothelial cells obtained from monkey ovulatory follicles (i.e., mOMECs) when maintained in vitro. Ours is one of few reports to examine the expression of all four PTGERs in the same population of endothelial cells [34, 35] . PTGERs on mOMECs generated appropriate intracellular signals in response to PTGER-selective agonists. Treatment with a PTGER1 agonist increased intracellular calcium. While data regarding PTGER1 signaling in vascular endothelial cells is limited, the ability of the PTGER1 agonist to increase intracellular calcium is consistent with the widely accepted view that PTGER1 typically couples to a G protein to enhance phospholipase C activity, inositol phosphate turnover, and calcium mobilization [36] . PTGER2 and PTGER4 agonists increased cAMP in mOMECs, while PTGER3 increased intracellular calcium but did not alter cAMP, consistent with observations in other cultured vascular endothelial cells [37] . Detection of PTGER4 protein in mOMECs was equivocal. However, the ability of a PTGER4 agonist to increase cAMP supports the presence of functional PTGER4 on follicular endothelial cells. Interestingly, PTGER4 and possibly PTGER2 appear to be located throughout mOMECs, while PTGER1 and PTGER3 appear to be excluded from the nucleus. Localization of functional PTGERs in both the plasma membrane and nuclear envelope have been previously reported [38] . Overall, these data support the concept that vascular endothelial cells in monkey follicles can respond to PGE2 via all four PTGERs.
The PTGER agonists and antagonists used in the present study are very well characterized, and selected doses were well within the ranges that interact with a single PTGER [36, [39] [40] [41] [42] [43] . The low expression of PTGER4 in mOMECs prompted investigation into the specificity of each PTGER agonist because it was possible that observed responses were due to off-target actions. Specific PTGER antagonists for each receptor were able to inhibit agonist-induced migration, supporting the conclusion that each receptor agonist is selective for a single PTGER at the dose used in this study. These data also demonstrate that PTGER4 is expressed and functional in endothelial cells, although perhaps at a lower level than the other PTGERs.
Capillaries forming in the luteinizing granulosa cell layer of the primate follicle likely branch from existing vessels in the stroma surrounding the follicle. The 3D reconstructions showed that endothelial cells detected in the granulosa cell layer form networks that connect with larger vessels located outside the granulosa cell layer, consistent with branching angiogenesis [44] . This model also predicts that capillary sprouts will meet to establish a tube and create a conduit for blood flow; the tip cell prevents blood flow until one sprout connects with another sprout. Our data suggest that capillaries of the luteinizing monkey follicle extend from the stroma to the antral edge of the luteinizing granulosa cell layer, with the capillary open and releasing red blood cells into the antral space just after ovulation. Previous studies have utilized vascular casting and microspheres to demonstrate the presence of vascular networks within the young corpus luteum but not the luteinizing follicle [45] . Capillaries connecting arterial and venous vasculature provide low resistance blood flow beginning a few days after ovulation [46] . However, lack of sufficient blood flow through developing capillaries in the luteinizing follicle may have prevented detection of these developing structures prior to ovulation.
New vessels may also arise from stem cells by the process of vasculogenesis [47] . PGE2 has been reported to induce endothelial differentiation from circulating bone marrowderived cells [48] , and focal appearance of endothelial cells arising from circulating progenitors has been proposed in the developing corpus luteum [47] . While vasculogenesis may contribute to capillary formation, the overall pattern of the newly forming capillary networks suggests that branching angiogenesis is likely very important to establishment of the new vascular bed within the luteinizing cells of the ovulatory follicle.
Branching angiogenesis requires endothelial cells of an existing vessel to proliferate and migrate to form a new capillary sprout. Perhaps surprisingly, PGE2 and PTGER agonists had no apparent impact on mOMEC proliferation. Previous studies provide conflicting information regarding the ability of PGE2 to regulate endothelial cell proliferation [34, 49] . Two well-characterized inducers of endothelial cell proliferation are VEGF and FGF2, both of which are produced by the ovulatory follicle [50] [51] [52] . The mOMECs did proliferate in EGM2 media, which contains growth-promoting agents, including VEGFA and FGF2. In addition to VEGF and FGF2, prolactin stimulates endothelial proliferation in the ovulatory follicle [53] . PGE2 may act in cooperation with these or other angiogenic factors to regulate proliferation [54] . Finally, PGE2 has been reported to increase VEGF expression while VEGF increased PGE2 production in human umbilical vein endothelial cells [55] , so PGE2, VEGF, and FGF2 may act synergistically to promote angiogenesis in the ovulatory follicle in vivo.
Migration of endothelial cells was observed both in vivo and in vitro in response to PGE2 and PTGER agonists. In addition, PTGER antagonists reduced or eliminated PGE2-induced migration, further indicating that all the PTGERs are involved in this aspect of angiogenesis. Previous reports found that PGE2 action via PTGER2 and PTGER4, but not PTGER1, induced pulmonary endothelial cell migration in vitro [34, 49] ; the role of PTGER3 in endothelial cell migration has not previously been explored. While VEGF stimulates endothelial cell migration in many experimental models, other migratory regulators include thymosin, thromboxane A2, and fibronectin [56] [57] [58] . Migration involves degradation and remodeling of extracellular matrix, extension and adhesion of filopodia, and the ability of an endothelial cell to follow a stimulus in a directional manner [59] . PGE2 is known to regulate the expression of proteases in the ovulatory follicle [60] , and the resulting proteolytic activity may facilitate ovarian endothelial cell migration.
Vascular sprouts were observed in vivo and in vitro in response to PGE2 and agonists selective for PTGER1 and PTGER2; PTGER3 and PTGER4 agonists did not promote sprout formation. Furthermore, sprouts produced in response to PTGER agonists had differing qualities. PTGER1 stimulated the formation of long, numerous, less-branched sprouts in vitro, consistent with the apparent sprouting seen reaching from the stroma to the follicle antrum in monkey follicles in vivo. PTGER2 stimulated the formation of numerous, shorter, branched sprouts in vitro, consistent with the limited penetration of endothelial cells into the granulosa cell layer in vivo. PTGER3 did not promote sprouting in vivo and actually reduced sprout formation in vitro. PTGER4 did not TRAU ET AL. increase sprout number or length above basal levels in vitro, consistent with the small number of endothelial cells observed among granulosa cells in vivo. While the ability of PTGER1 to regulate endothelial cell sprout formation has not been previously reported, PTGER2 and PTGER4 have both been reported to induce sprouting [34, 35, 61] . PTGER2 has been specifically linked to branching of sprouts [49] , while PTGER3 has been previously reported as failing to induce sprout formation [61] , consistent with our observations. PTGER2 has also been identified as the key PTGER mediating the actions of PGE2 to stimulate luteal endothelial cells to form tubelike structures in an in vitro model of angiogenesis [61] . Our study extends this finding to identify both PTGER1 and PTGER2 as likely mediators of PGE2-stimulated vascular sprouting in the ovulatory follicle.
Overall, these data provide strong support for the concept that PGE2 acts directly at endothelial cells to promote angiogenesis of the primate ovulatory follicle. While PGE2 action at additional cell types likely contributes to follicular angiogenesis, endothelial cells are clearly a target for PGE2 action. All four PGE2 receptors were expressed and functional in follicular endothelial cells. PTGER1 and PTGER2 agonists stimulated endothelial cell migration and sprout formation in vitro; these agonists also restored aspects of indomethacininhibited formation of endothelial networks reminiscent of capillaries in the monkey luteinizing follicle in vivo. In contrast, PTGER3 and PTGER4 promoted migration in vitro but had minimal impact on endothelial network formation in vivo. In fact, PTGER3 appears to actively inhibit sprout formation, a key aspect of angiogenesis. These receptors were localized to endothelial cells of stromal vessels as well as endothelial cells in the luteinizing granulosa cell layer, so PTGER3 and PTGER4 may play roles in vessel stability. It is interesting to note that PTGER3 and PTGER4 receptors require lower levels of PGE2 for maximal activation than do PTGER1 and PTGER2 [36] . PTGER3 and PTGER4 may be key receptors at low PGE2 concentrations, while high PGE2 concentrations like those in the ovulatory follicle provide additional stimulus through PTGER1 and PTGER2 to promote ovulatory events, including angiogenesis of the luteinizing follicle.
